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Introduction
Synthetic biomaterials have been developed and improved 
over more than five decades as an alternative to natural bone 
grafts. Among other benefits, synthetic bone graft substitutes 
could overcome the limited availability of autologous bone 
grafts, an issue that is becoming increasingly important with 
continuous population aging. To be accepted as a comprehen-
sive alternative to natural bone, synthetic bone graft substitutes 
need to meet a number of requirements, including provision of 
mechanical support, and bioactivity in terms of osteoconductiv-
ity and osteoinductivity. While the existing synthetic bone graft 
substitutes are generally accepted as being osteoconductive, i.e., 
able to promote “the recruitment and migration of osteogenic 
cells into the wound site,”1 recent research efforts have strongly 
focused on osteoinductivity of materials, defined by Friedenstein 
as “the induction of undifferentiated inducible osteoprogenitor 
cells that are not yet committed to the osteogenic lineage to form 
osteoprogenitor cells,”2 because osteoinductivity is considered to 
be essential for successful healing of large, critically sized bone 
defects. The exact mechanism of osteoinduction by synthetic bio-
materials has not yet been fully deciphered; however, a growing 
number of materials has shown osteoinductive potential, demon-
strated by the induction of bone formation upon implantation 
in heterotopic sites such as muscle or subcutis in various animal 
models. While osteoinduction has occasionally been shown for 
polymers3 and porous metals,4 biomaterials with osteoinductive 
potential are mainly calcium-phosphate (CaP) ceramics. With 
chemical compositions close to that of bone mineral, CaP ceram-
ics have logically raised considerable interest in bone regenera-
tion. Previous studies have recorded heterotopic bone formation 
in, among others, hydroxyapatite (HA),5 β-tricalcium phosphate 
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Synthetic bone graft substitutes based on composites consisting of a polymer and a calcium-phosphate (Cap) ceramic 
are developed with the aim to satisfy both mechanical and bioactivity requirements for successful bone regeneration. 
In the present study, we have employed extrusion to produce a composite consisting of 50 wt.% poly(D,L-lactic acid) 
(pLA) and 50 wt.% nano-sized hydroxyapatite (HA) powder, achieving homogeneous distribution of the ceramic within 
the polymeric phase. In vitro, in both a simulated physiological saline (SpS) and a simulated body fluid (SBF), a greater 
weight loss was observed for pLA/HA than for pLA particles upon 12-week immersion. Furthermore, in SpS, a continu-
ous release of calcium and phosphate from the composite was measured, whereas in SBF, decrease of the amount of the 
two ions in the solution was observed both for pLA and pLA/HA accompanied with the formation of a Cap layer on the 
surface. In vitro characterization of the composite bioactivity was performed by culturing human mesenchymal stromal 
cells (hMSCs) and assessing proliferation and osteogenic differentiation, with pLA as a control. Both pLA/HA composite 
and pLA control were shown to support hMSCs proliferation over a period of two weeks. In addition, the composite sig-
nificantly enhanced alkaline phosphatase (ALp) activity of hMSCs in osteogenic medium as compared with the polymer 
control. A novel implant design was employed to develop implants from dense, extruded materials, suitable for testing 
osteoinductivity in vivo. In a preliminary study in dogs, pLA/HA composite implants induced heterotopic bone formation 
upon 12-week intramuscular implantation in all animals, in contrast to pLA control, which was not osteoinductive. Unlike 
in vitro, a more pronounced degradation of pLA was observed in vivo as compared with pLA/HA composite.
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(β-TCP),6 biphasic calcium phosphate (BCP) (a mixture of HA 
and β-TCP),7 brushite8 and octacalcium phosphate9 in various 
animal models.
While CaP ceramics have shown the strongest osteoinductive 
potential among synthetic materials, intrinsic brittleness lim-
its their use as bone graft substitutes to non-load bearing sites. 
This could possibly be overcome by the development of com-
posite materials. Combinations of polymers and ceramics offer 
numerous opportunities for improving the mechanical proper-
ties of ceramics while retaining their bioactivity.10 For example, 
composites based on polylactic acid (PLA), a biocompatible and 
biodegradable aliphatic polyester and HA have been investi-
gated as potential bone graft substitutes in a number of studies. 
Addition of HA microparticles to PLA was shown to increase 
the compressive and bending strengths in a dose-dependent 
manner.11 Similarly, diametral tensile strength of PLA improved 
upon incorporation of HA.12 In the study by Nejati et al. it 
was furthermore shown that the size of ceramic particles can 
be used to tailor mechanical properties of the composites: HA 
nanoparticles increased the compressive strength of the compos-
ite in comparison to HA microparticles, making it comparable 
to cancellous bone.13 In vitro, support of attachment and growth 
of MSCs and (pre)osteoblasts has been described in a number 
of studies.13-16 In vivo, porous composites made of PLA and HA 
microparticles were shown osteoconductive when implanted in 
a 6 mm defect in a rabbit femoral intercondylar notch model.17 
Similarly, porous PLA/HA composite materials produced using 
gas foaming showed successful healing of a critical-sized cranial 
defect in rats.18 Osteoinductivity of a PLA/HA porous composite 
produced using a solvent-based method was demonstrated upon 
intramuscular implantation in dogs.19,20
Besides chemistry, structural properties of biomaterials 
have also been suggested to affect level of osteoinductivity.21 
Microporosity, for instance, contributes to this phenomenon: an 
increase in microporosity and specific surface area of a ceramic 
has been shown to lead to a higher osteoinductive potential.22,23 
Geometrical features of the materials at the macroscopic level 
have also been shown to strongly affect material-induced bone 
formation. Indeed, heterotopic bone formation has been shown 
to preferentially form inside pores, channels and concavities and 
rarely on the implant periphery,8,24 suggesting that “protected” 
environment inside the material is required for osteoinduction to 
occur and/or be maintained.
In the current study, a PLA/HA composite was developed 
using extrusion, a manufacturing technique that does not require 
the use of solvents. In vitro, human mesenchymal stromal cells 
(hMSCs) were cultured on the composite material and prolif-
eration and osteogenic differentiation were assessed, with PLA 
as a control. Furthermore, the osteoinductive potential of the 
composite was investigated in a preliminary in vivo study in a 
canine intramuscular model. Since extruded materials are dense, 
not containing “natural” protected areas like pores or channels, 
we designed the implants such that an “artificial pore” is created 
between plates of extruded materials in order to test the ability 




The HA powder was phase-pure as determined by XRD anal-
ysis (Fig. 2A) and had a particle size of 69.9 ± 12.8 nm in width 
and 308.7 ± 61.2 nm in length (Fig. 2B), as determined by SEM 
imaging. FTIR spectra of PLA and PLA/HA composite powders 
are shown in Figure 2C. In contrast to PLA control, PLA/HA 
composite spectrum contained phosphate (604 and 562 cm-1) 
and hydroxyl (632 cm-1) bands, characteristic of HA, confirming 
incorporation of the ceramic in the polymer phase.25 A modifica-
tion of the main PLA peak (symmetric and asymmetric defor-
mational vibrations of C–H in CH
3
 groups), was observed in the 
composite spectrum around 1000 cm-1 due to the HA phosphate 
band situated at the same wavelength. The pronounced intensi-
ties of HA-specific bands in the composite spectrum are in line 
with the quantity of HA incorporated.
Figure 1. Implant design. Digital photograph (A) and schematic representation with dimensions (B) of implants used for intramuscular implantation in 
a canine model to assess osteoinductivity.
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EDAX analysis of a gold-sputtered PLA/HA pellet, after pol-
ishing and sterilization, confirmed presence of HA by the pro-
nounced calcium and phosphorus peaks in the EDAX spectrum 
(Fig. 3A and B), while no calcium or phosphorus was observed in 
the spectrum of the PLA control (data not shown). Phosphorous 
and calcium mapping of PLA/HA composite showed homoge-
neous distribution of both elements (Fig. 3C and D).
Calcium and phosphate release and degradation study
Degradation and ion release tests were performed on material 
particles with a size of 0.5–1 mm. The behavior in an aqueous 
environment of PLA/HA composite and PLA control materials 
was tested over three months in SPS, a buffered solution with an 
ionic strength similar to that of blood plasma, and in SBF, which 
mimics the mineral composition of blood plasma and is saturated 
toward dicalcium phosphate dihydrate (Fig. 4). Measurements 
of the wet weight of the immersed particles showed that the PLA 
water uptake approximately doubled the initial dry weight of the 
particles after 12 wk of immersion in both solutions. The swell-
ing of PLA/HA particles appeared to be less pronounced with a 
wet weight increase of approximately 1.5 times the initial weight 
(Fig. 4A). After drying, particles were weighed again to assess the 
mass loss. While no measurable decrease could be detected in the 
case of PLA particles in either solution, the dry weight of PLA/
HA particles decreased with about 4% in SPS and with about 
7% in SBF over the three months of the experiment. The pH of 
SPS and SBF solutions was stable over time in the case of PLA 
particles, whereas for PLA/HA particles a decrease from 7.32 to 
6.92 was observed in SPS and from 8.53 to 7.16 in SBF between 
12 h and 12 wk of immersion (Fig. 4B).
Release of calcium and phosphate from the PLA/HA com-
posite was measured in SPS and SBF solutions over the time 
of the degradation study (Fig. 4C–F). In SPS, calcium signal 
was first detected after two weeks of immersion, whereas phos-
phate was detected as early as one week after immersion in SPS. 
A continuous release of both calcium and phosphate from the 
composite was observed during the time frame tested, without 
reaching a plateau. No calcium or phosphate was observed in SPS 
upon immersion of PLA particles over the 12-wk period. In the 
case of samples immersed in SBF, precipitation occurred shortly 
after mixing of the salts, leading to a milky solution after 12 h. 
Simultaneously, the concentrations of calcium and phosphate 
dropped over the first week of immersion for both PLA and PLA/
HA, before reaching a plateau. For PLA/HA samples, an increase 
in concentration of calcium and phosphate was observed at 8 and 
10 wk, respectively.
The SEM micrographs of cross-sections of PLA and PLA/HA 
particles, immersed for 12 wk in SPS, showed a dense surface of 
both PLA and PLA/HA. Underneath the surface, the material 
was porous in the case of PLA particles, whereas in the PLA/
HA particles a dense “core” could still be observed (Fig. S1A 
and B). For samples immersed in SBF, the SEM micrographs 
of both PLA and PLA/HA particles surfaces, showed the for-
mation of globular precipitates, which were identified as CaP by 
EDAX analysis (data not shown). The deposition of this layer 
was observed as early as 12 h upon immersion, and at all later 
time points. After 12 wk in SBF, PLA particle surface exhibited 
holes suggesting degradation, and deposits of CaP. Similar CaP 
deposits were observed on PLA/HA particles with porous bulk 
material underneath the surface (Fig. S1C and D).
HMSCs proliferation and osteogenic differentiation
For in vitro cell culture experiments, PLA and PLA/HA pel-
lets with a diameter of 10 mm and a thickness of 2 mm were 
seeded with hMSCs. DNA was quantified after 7 and 14 d of 
culture in basic and osteogenic medium as an indirect measure 
of cell proliferation (Fig. 5A). Both PLA/HA composite and PLA 
control sustained hMSCs proliferation over the 2-wk culture 
period. A significant increase in DNA amounts between day 7 
and day 14 was observed for cells cultured in basic medium on 
both PLA and PLA/HA. An increase in time was also observed 
for cells cultured in osteogenic medium on both material types, 
however, the differences were not statistically significant. No 
differences between PLA and PLA/HA were observed at either 
time point, independent of the medium used. Similarly, no effect 
of the medium type on cell proliferation was observed on either 
material type at days 7 and 14.
ALP activity of hMSCs was quantified and corrected for 
DNA content after 7 and 14 d of culture in basic and osteogenic 
medium (Fig. 5B). In osteogenic medium, ALP level increased 
between 7 and 14 d on both PLA/HA composite and PLA 
control, although a statistically significant increase was only 
Figure 2. Characterization of pLA, pLA/HA and HA. XRD spectrum of nano-HA powder (A), SeM micrograph of nano-HA powder (B), and FtIR spectra of 
nano-HA powder, pLA and pLA/HA composite (C).
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observed for PLA/HA. No temporal increase was observed when 
cells were cultured in basic medium. Regarding the effect of the 
material type, the trend observed was that, independent of the 
medium used, ALP level of hMSCs cultured on PLA/HA com-
posite was higher than that of cells cultured on PLA control at 
both 7 and 14 d. The difference in ALP expression between cells 
cultured on PLA/HA and PLA was, however, only statistically 
significant after 14 d in osteogenic medium.
Osteoinductive potential
For the in vivo study, implants were used that consisted of 
two paired identical plates of PLA or PLA/HA composite with 
a size of 24 × 14 × 5 mm3 with two 0.5 mm thick PEOT/PBT 
spacers between them (Fig. 1). There were no surgical complica-
tions and all animals experienced an uneventful recovery from 
the surgery. At implant retrieval, no clinical signs of inflamma-
tion or infection (i.e., swelling or redness) were observed upon 
visual inspection of the implantation area. Only two out of five 
implanted PLA samples were found and explanted. In the areas 
where the remaining three PLA samples were implanted, no mate-
rial remnants or signs of tissue other than muscle were observed. 
In contrast, all 12 implanted PLA/HA samples were retrieved, 
and while 2 were lost during processing (dissolved in MMA 
monomer), 10 could be histologically analyzed. Macroscopic 
and microscopic observation showed that a fibrous capsule with 
a thickness varying between 50 and 200 µm had formed around 
all samples of both PLA and PLA/HA (Fig. 6A-–D). The 
fibrous capsule seemed somewhat thicker around the PLA than 
around the PLA/HA implants, but as only two PLA samples 
were retrieved, a good comparison was difficult to make. The 
PLA samples were largely degraded (Fig. 6A–C) which may be 
an explanation why the remaining three samples were impos-
sible to trace at explantation. Degradation of composite sam-
ples appeared to be less pronounced than that of PLA control 
(Fig. 6B). Analysis of the samples showed that in all cases, the 
PEOT/PBT spacers used to create the gap between the two bio-
material plates were completely degraded. As a result, the two 
plates were in close contact with each other, limiting ingrowth 
of tissue inside the implant. The unexpected degradation of 
spacers, and thus loss of the gap were attributed to the improper 
choice of PEOT/PBT copolymer composition. Microscopic 
analysis of tissue formed around the implants showed no signs 
of bone formation or mineralization in PLA controls (Fig. 6C). 
Fibrous tissue surrounding PLA/HA implants contained no 
mineral or bone either, however, in all 10 analyzed PLA/HA 
Figure 3. Composite homogeneity. SeM micrograph (A), eDAX spectrum (B) and elemental maps of calcium (C) and phosphorous (D) atoms of pLA/HA 
pellet after polishing and sterilization. (scale bars: 20 μm).
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samples, heterotopic bone formation was observed inside the 
implants, particularly in the areas where the original entrance 
of the gap between the two material plates was located (Fig. 7A 
and B). Based on qualitative observations, the amount of bone 
formation was relatively limited. Nevertheless, the maximum 
depth of ingrowth of bone into the implant was observed to be 
about 4 mm. Newly formed bone was normal in appearance, 
showing mineralized matrix aligned with a layer of osteoblasts 
(Fig. 7C and D.). Another qualitative observation suggested 
that heterotopic bone formation was most pronounced in the 
highly degraded areas of implant (Fig. 7E).
Discussion
Synthesis of ceramic/polymer composite materials by extru-
sion does not require use of organic solvents, which is an 
Figure 4. In vitro degradation and calcium phosphate release. Wet and dry weights of the pLA and pLA/HA particles upon immersion in SpS and SBF 
over a period of 12 wk. (A) pH of the solutions. (B) Calcium and phosphate release from pLA/HA particles in SpS (C and D respectively) and of pLA and 
pLA/HA in SBF (E and F respectively). Statistical analysis was performed using one way ANoVA with tukey’s multiple comparison post-hoc test (P < 0.05 
and n = 3).
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important advantage when aiming for implantable materials, as 
remnants of solvents are difficult to completely remove from the 
material.26 In the present study, we have confirmed that up to 50 
wt% nano-sized HA particles can homogeneously be incorpo-
rated into PLA by using extrusion. Previous studies performed on 
PLA and HA blends have shown that presence of ceramic in the 
polymeric matrix has a dose dependent effect on various prop-
erties of the polymer, such as mechanical behavior, degradation 
rate, and bioactivity.11,20,27,28 Verheyen et al. have demonstrated 
that a 50 wt% content of HA mixed with PLA improved the 
osteoconductivity as compared with the polymeric control in a 
transcortical implantation model in goats.27 Hasegawa and col-
leagues provided first evidence for osteoinduction by porous scaf-
folds made of PDLLA/HA composite with a weight ratio 70/30, 
upon intramuscular implantation in dogs.19 In contrast, no het-
erotopic bone formation was observed in PDLLA scaffolds with-
out HA. In a study by Barbieri et al., in which porous PDLLA/
nano apatite composites with a ceramic content of 10 wt%, 20 
wt% and 40 wt% produced using a solvent-based method were 
tested, only the composite with 40 wt% apatite led to hetero-
topic bone formation upon intramuscular implantation in dogs 
for 12 wk.20 In a more recent study by Barbieri et al., a similar 
PDLLA/nano apatite blend with a ceramic content of 50 wt% 
produced by extrusion was shown to trigger osteoinduction in a 
sheep intramuscular model.29 Regarding the extrusion process, 
it could be argued that a temperature of 150 °C may affect the 
molecular weight of the polymer, as PLA is known to be tempera-
ture sensitive.30 Analysis of polymer before and after extrusion 
using Ubbelohde viscosimeter, however showed a minor effect of 
the extrusion process on molecular weight of the polymer (data 
not shown). It has previously been suggested that ceramic fillers 
limit the thermal degradation of the polymer during extrusion,30 
while the amount of ceramic incorporated correlates with fric-
tional degradation.28
Degradation is a critical parameter of biomaterials. In the case 
of bone graft substitutes, degradation rate of the material should 
be comparable to the rate of new bone formation, in order for 
the material to provide sufficient support while leaving space for 
tissue growth. Degradation must therefore be controlled. PLA 
is known to undergo autocatalytic hydrolysis, producing lac-
tic acid, and its degradation rate is strongly influenced by the 
molecular weight: the lower the molecular weight is, the faster 
PLA degrades.29,31 Indeed, strong degradation of PLA occurred 
upon implantation of the polymer in paraspinal muscles of dogs, 
to the extent that a number of implants could not be retrieved 
from the animals 12 wk after implantation. This level of degra-
dation is not surprising, considering the low molecular weight of 
the polymer used. Although degradation of PLA/HA implants 
was also observed, its extent was significantly lower than that 
of PLA, which could be explained by the buffering effect of the 
ceramic phase of the composite that hampered the autocatalytic 
degradation of the polymer. The observed decrease in degrada-
tion of PLA/HA composite as compared with the PLA control 
was in accordance with earlier studies.32,33 Degradation of the 
polymeric phase of the composite is also crucial for the release 
of calcium and phosphate ions from the ceramic phase, which is 
suggested to be the origin of bioactivity of CaPs.34,35 For exam-
ple, in vitro effects of free calcium ions have been extensively 
studied on various cell types, including hMSCs,36 osteoblasts,37 
macrophages,38 human periosteum-derived cells (hPDCs),39 etc. 
Calcium ions have shown to influence the proliferation, mor-
phology and osteogenic differentiation of hMSCs.36 Similarly, 
in vitro studies on the effect of inorganic phosphate ions have 
shown a concentration-dependent effect on osteogenic differ-
entiation of hPDCs,39 whereas osteoblast-like cells were shown 
to undergo apoptosis when treated with high levels of inorganic 
phosphate.40 On the other hand, hypophosphatemia has been 
shown to inhibit osteoclast formation and osteoblast differentia-
tion to mature osteocytes.41 Despite this body of evidence for the 
Figure 5. HMSCs proliferation and osteogenic differentiation. DNA content (A) and ALp activity corrected for DNA content (B) of hMSCs cultured on 
pLA and pLA/HA pellets in basic and osteogenic medium for 7 and 14 d. Statistical analysis was performed using one way ANoVA with tukey’s multiple 
comparison post-hoc test (P < 0.05 and n = 3).
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effect of free calcium and phosphate ions on cell proliferation and 
osteogenic differentiation, as we recently reviewed, it is difficult 
to pinpoint a single parameter that is responsible for biological 
response to a CaP material in vitro or in vivo.21 Release of cal-
cium from a CaP ceramic is accompanied by other events, such 
as phosphate release, reprecipitation of a biological apatite layer, 
possibly containing endogenous proteins and other factors, and 
change of surface topography, all of which can affect bioactivity 
of the material as well. In our study, we have demonstrated a 
continuous release of calcium and phosphate ions from the com-
posite over 12 wk in SPS in vitro. In addition, a small but more 
pronounced weight loss was observed for PLA/HA composite 
particles as compared with PLA control particles along with a 
stronger decrease of pH of the solution. SPS is a solution with 
ionic strength similar to the blood plasma, but it is, unlike blood 
plasma not saturated toward dicalcium phosphate dihydrate. 
Upon immersion in SBF, which simulates the mineral composi-
tion of blood plasma, weight loss of PLA/HA particles was again 
more pronounced than that of PLA particles, and so was the pH 
decrease. However, a decrease of calcium and phosphate ions 
measured was probably a consequence of the formation of a CaP 
layer on the surface of both PLA and PLA/HA. In the case of 
PLA/HA, an increase in calcium and phosphate concentrations 
in SBF at the latest time points may be attributed to the drop in 
pH observed. Although SBF is theoretically supposed to better 
mimic the mineral composition of body fluids,42 in vivo condi-
tions of fluid refreshment regimes, local pH, temperature and 
presence of endogenous factors are difficult, if not impossible to 
mimic in vitro, which is why release data as described here can 
at best be considered an indication of whether or not ions release 
from the composite material takes place, and to which extent this 
release is dependent on the degradation of the polymer phase. 
Nevertheless, considering clear signs of PLA/HA degradation in 
vivo, and differences in the extent of degradation between the 
polymer and the composite, it is plausible that release of calcium 
and phosphate from the ceramic phase occurred in parallel.
Both PLA/HA composite and PLA control sustained prolif-
eration of hMSCs over a period of 14 d. In general PLA is con-
sidered a biocompatible material, and indeed in our study no 
detrimental effects on cell proliferation were observed within the 
time frame cultured, which was in accordance with a study in 
which MC3T3-E1 osteoblast were cultured on electrospun PLA 
and PLA/HA fibers.14 While no effect of material or medium 
type was observed, cell numbers on both PLA/HA and PLA 
increased between days 7 and 14, independent of the cell culture 
medium used. This increase was, however, less pronounced for 
PLA/HA in osteogenic medium than for the other conditions, 
which may be explained by an increase in osteogenic differentia-
tion, as was demonstrated by a significant increase in ALP levels 
of cells cultured on PLA/HA in osteogenic medium, between 
Figure 6. In vivo degradation of implants and formation of fibrous capsule. Images of methylene blue and basic fuchsin stained histological sections of 
implants after 12-wk intramuscular implantation in dogs. Digital photographs of a pLA (A) and a pLA/HA (B) implant section (scale bars: 5 mm), showing 
a more pronounced degradation of the polymer as compared with the composite implant. High magnification micrographs of a pLA (C) and a pLA/HA 
(D) implant section, showing fibrous capsule (FC) that had formed around both implant types and the surrounding muscle tissue (M) (scale bars: 100 µm).
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days 7 and 14. A trend of ALP levels of cells cultured on PLA/
HA being higher than those on PLA control was observed at both 
time points and in both basic and osteogenic medium, although 
the difference was only significant at 14 d in osteogenic medium. 
These data suggest that PLA/HA composite improved osteo-
genic differentiation of hMSCs as compared with PLA without 
the ceramic and are in accordance with earlier studies using fetal 
bone cells.43
In vivo, although some cases of inflammatory response were 
reported upon PLA implantation, this polymer is considered to 
have an overall satisfactory biocompatibility.44 In our in vivo 
study, the thin dense fibrous capsule observed around both PLA 
and PLA/HA implants after 12 wk of intramuscular implanta-
tion in dogs, suggested a mild tissue response.45 Presence of bone 
in all PLA/HA samples implanted intramuscularly was the proof 
of osteoinductivity of the composite. Previous studies already 
reported osteoconductivity27 and osteoinductivity19,20,29 of PLA/
Figure 7. In vivo bone formation in composite implants. Low magnification micrographs (A and B) and enlargements of black square areas in (A and 
B), respectively (C and D) of representative methylene blue and basic fuchsin stained sections of pLA/HA composite implants from two dogs. Images (A 
and B) show the entrance of the protective gap between the two composite plates surrounded with fibrous tissue (Ft). Bone formation can be observed 
inside the gap (Bone). the newly formed bone was normal in appearance, with osteoid containing osteocytes and aligned with a layer of osteoblasts 
(C and D). Bone formation was also observed surrounding composite particles formed upon degradation (indicated by arrows, scale bars: A and B, 500 
µm; C and D, 50 µm; E, 200 µm).
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HA blends. While use of solvents may be a disadvantage, solvent-
based methods typically result in porous materials, in contrast 
to extruded material particles, which are dense. As stated ear-
lier, protective areas in an implant, in the form of concavities, 
channels or pores are considered essential for osteoinduction to 
occur.21 For this reason, implants for the in vivo part of this study 
were designed such that a protective area was artificially created 
between two dense composite plates. With improvement of the 
choice of spacer material, such as Teflon, the implant design 
with the protective gap is expected to retain its shape to allow 
formation of bone even deeper inside the gap. The observation 
that bone formation was primarily observed in the areas close to 
the original openings of the gap and in the areas of pronounced 
degradation of the composite were in accordance with results 
from an earlier study in which calcium phosphate cement blocks 
with open and closed channels were tested for osteoinductivity.8 
This observation could be related to a better oxygen and nutri-
ent supply in the areas close to gap openings as well as to better 
availability of calcium phosphate ceramic in the areas of strong 
degradation of the composite. Indeed, considering that no bone 
was found in PLA implants, despite extensive degradation, it is 
suggested that bone formation observed in PLA/HA implants 
was related to increased availability of the HA ceramic and ionic 
dissolution/reprecipitation processes occurring in the vicinity of 
HA particles. Despite the unexpectedly fast degradation of the 
material used for spacer in the 3D implants, we have shown that 
osteoinduction by the PLA/HA composite produced by extru-
sion is possible, when dense materials are shaped into an implant 
that allows bone induction. In general, such dense materials may 
be interesting in studies aiming to describe the effect of indi-
vidual material parameters in phenomena such as osteoinduction, 
for example, by allowing the change of a single parameter, such 
as ceramic phase without variability in macro- or microporosity.
Materials and Methods
Materials production and characterization
The composite used in this study consisted of 50 wt.% amor-
phous poly(D,L-lactic acid) (PLA), (ANaBior or Purac), and 50 
wt.% in-house made nano-sized HA powder. HA was produced 
using a wet precipitation method as described earlier.20 In short, 













mixed at a pH above 10, and the resulting powder was allowed to 
age, washed and finally resuspended in acetone. A low molecu-
lar weight of 55,000 – 59,000 Da was chosen for PLA in order 
to build a rapidly degradable composite. Characterization of 
the HA powder was performed using X-ray diffraction (XRD, 
Rigaku Miniflex) and an environmental scanning electron 
microscope (SEM; XL30, ESEM-FEG, Philips) in the second-
ary electron mode with an acceleration voltage of 20 kV (Fig. 2A 
and B). Composite was produced by extrusion using a twin 
screw extruder with conical non-converging screws (Artecs BV, 
Enschede, the Netherlands). The extruder was set at 150 °C and 
the screw rotation speed at 100 rpm, which allowed the com-
posite to flow out of the extruder after a mixing time of 5 min. 
Controls made of PLA were prepared using the same process. 
Following extrusion, PLA/HA composite and PLA control were 
shaped into particles, pellets and complex three-dimensional 
implants to be used for the degradation study, in vitro evaluation 
and in vivo implantation respectively.
Chemical characterization was performed using transmission 
mode Fourier Transform Infrared spectroscopy with KBr pellets 
(FTIR; Spectrum100, Perkin Elmer Analytical Instruments). 
Surface morphology and homogeneity of the ceramic distribu-
tion in the polymeric phase were assessed for sterilized PLA/HA 
and PLA pellets using SEM with an acceleration voltage of 5 kV, 
coupled to energy dispersive X-ray analyzer (EDAX; Apollo X, 
Ametek).
In vitro degradation and ion release dynamics
For the degradation study, material particles with a size of 
0.5–1 mm were produced by grinding and subsequent sieving 
of the extruded material. 100 mg of particles were immersed in 
5 ml of either simulated physiological saline (SPS) or simulated 
body fluid (SBF) in triplicate. SPS contained 137 mM Na+, 177 
mM Cl- and 50 mM 4-(2-hydroxyethyl)-1-piperazineethane-
sulfonic acid (HEPES). The pH of SPS was adjusted to 7.3 using 
1 M NaOH. SBF was prepared using the method proposed by 
Bohner and Lemaitre42 and contained 142 mM Na+, 109.90 mM 
Cl-, 34.88 mM HCO
3
-, 2.31 mM Ca2+ and 1.39 mM HPO
4
2-. 
The pH of SBF was adjusted to 7.4 using 1 M HCl. Samples were 
placed in a shaking waterbath at 37 °C for a maximum of three 
months. Calcium and phosphate concentrations and the pH of 
the solutions were analyzed after 12 h, 1, 2, 4, 6, 8, 10 and 12 wk. 
Calcium and phosphate concentrations were determined using 
a quantitative colorimetric method (QuantiChromTM Calcium 
assay kit (DICA-500) and QuantiChromTM Phosphate assay kit 
(DIPI-500), respectively). Optical density of solutions after add-
ing reagents from the kits was read with a microplate spectropho-
tometer (Thermo Scientific Multiskan GO) at 612 nm and 620 
nm for calcium and phosphate release, respectively. The degra-
dation experiment was performed on independent triplicates for 
the time points 1, 4, 8 and 12 wk. The intermediate measures of 
calcium and phosphate concentrations after 12 h, 2, 6, and 10 
wk were performed by sampling 300 µL of solution, which was 
not refreshed, from the independent triplicates aforementioned. 
This procedure was selected to avoid the error induced by solu-
tion refreshment. The material particles were collected, rinsed 
with MilliQ water and air-dried for two days before being char-
acterized by SEM. The wet and the dry weights of the particles 
were recorded after 12 h and 12 wk of immersion in SPS or SBF.
In vitro cell culture
Bone marrow aspirates were obtained after written informed 
consent, and hMSCs were isolated and proliferated as described 
previously.46,47 Briefly, aspirates were resuspended by using 
20-gauge needles, plated at a density of 5 × 105 cells/cm2 and 
cultured in hMSC proliferation medium containing α-minimal 
essential medium (Gibco), 10% fetal bovine serum (Lonza), 
0.2 mM ascorbic acid (Sigma Aldrich), 2 mM L-glutamine 
(Gibco), 100 units/ml penicillin (Gibco), 10 μg/ml streptomy-
cin (Gibco), and 1 ng/ml basic fibroblast growth factor (FGF) 
(Fisher Scientific). Cells were grown at 37 °C in a humid atmo-
sphere with 5% CO
2
. Medium was refreshed twice a week, and 
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cells were used for further sub-culturing or cryopreservation. 
Cells were trypsinised prior to seeding on materials.
For in vitro cell culture experiments, the extruded rods of PLA 
and PLA/HA composite were molded into pellets with a diam-
eter of 10 mm and a thickness of 2 mm using a Teflon mold 
and a heating press at 120 °C and 20 kN for 5 min. Pellets were 
then polished using sandpaper (grades 500 and 2400) to ensure 
a smooth surface. After sterilization with 70% isopropanol for 
two times 3 min and complete evaporation at room tempera-
ture, pellets were placed in ultra-low attachment 24 well-plates 
(Corning) to minimize the adhesion of cells to the plate. Prior 
to cell seeding, pellets were conditioned overnight in prolifera-
tion medium. 4000 hMSCs of passage 3 were seeded on each 
pellet in proliferation medium. After 24 h, proliferation medium 
was replaced by either basic (proliferation medium without FGF) 
or differentiation medium (basic medium supplemented with 
10nM dexamethasone). Cells were cultured for 7 and 14 d at 
37 °C in a humid atmosphere with 5% CO
2
, with refreshment of 
medium every 2 to 3 d. HMSCs proliferation was evaluated by 
quantifying DNA content (CyQUANT® Cell Proliferation assay) 
and ALP production was assessed at the enzymatic level (CDP-
Star® Reagent) as an early marker for osteogenic differentiation. 
Expression of ALP by hMSCs cultured on tissue culture plastic 
under osteogenic conditions has been shown to occur at around 
day 11,48 whereas on different biomaterials, including polymer/
ceramic composites, hMSCs have been shown to express ALP 
even earlier,49 which is why we selected 7 and 14 d of culture 
as endpoints for our in vitro experiment. All analyses were per-
formed in triplicate.
In vivo study
Implant preparation and implantation procedure
Implants were produced by molding the extruded rods of 
PLA and PLA/HA composite into 24 × 14 × 5 mm3 plates by 
using a poly(dimethylsiloxane) mold with smooth surface, two 
microscope glass slides and 2-foldback clips, by applying pres-
sure. The setup was left at 120 °C for 5 min. Upon removal from 
the mold, the plates were paired and glued together with smooth 
surfaces facing one another using a 0.5 mm thick poly(ethylene 
oxide terephthalate)/poly(butylene terephtalate) - (PEOT/
PBT) (PolyVation BV) spacers and super glue (Pattex) (Fig. 1). 
Following an aPEOTbPBTc nomenclature, the composition used 
in this study was 300PEOT55PBT45 where, (a) is the molecu-
lar weight in g/mol of the starting poly(ethylene glycol) (PEG) 
blocks used in the copolymerisation, while (b) and (c) are the 
weight ratios of the PEOT and PBT blocks, respectively. Prior to 
implantation, samples were sterilized by ethylene oxide (Isotron 
Nederland BV).
Twelve PLA-HA composite and 5 PLA control implants were 
inserted in paraspinal muscles of 8 skeletally mature male mon-
grel dogs (1–4 y old, weighing 10–15 kg) upon approval by the 
local animal care committee (Animal Center, Sichuan University, 
Chengdu, China; protocol P11029). The surgical procedure was 
performed under general anesthesia of the animals (pentobarbi-
tal sodium, Merck; 30 mg/kg body weight). After shaving the 
lumbar area and disinfection of the skin with iodine, the paraspi-
nal muscles were exposed. Using blunt dissection, intramuscular 
pockets were created bilaterally, and each pocket was filled with 
one implant. Distance among pockets was sufficient to avoid 
effect of individual implants on each other’s behavior. Upon 
implant placement, the wound was closed in layers using silk 
sutures. Following the surgeries, animals were given buprenor-
phine (0.1 mg per animal) intramuscularly for 2 d as analgesics 
and penicillin (40 mg/kg) by intramuscular injection for 3 con-
secutive days to prevent infection. Twelve weeks after implanta-
tion, the animals were sacrificed with overdose of pentobarbital 
sodium to harvest the samples.
Histological analysis
After explantation, samples, with surrounding muscle tissue 
were fixed in 4% buffered paraformaldehyde (pH 7.4) and kept at 
4 °C for one week. Fixed samples were rinsed with phosphate buf-
fer solution (PBS), dehydrated by ethanol series (70–100%) and 
infiltrated with a methylmethacrylate (MMA, LTI Nederland) 
solution that polymerized at 30 °C within 1 wk. Longitudinal 
non-decalcified sections with a thickness of 10–15 μm were cut 
using a diamond saw microtome (Leica Leitz 1600) and stained 
with 1% methylene blue and 0.3% basic fuchsin after etching 
with an HCl/ethanol mixture.
Tissue formation was qualitatively analyzed using a light 
microscope (Nikon Eclipse E600, DS Cooled Camera Head 
DS-Fi1c).
Statistical analysis
One way ANOVA with Tukey’s multiple comparison post-hoc 
test was performed to analyze weight measurements of the mate-
rials upon degradation study and DNA and ALP values following 
cell culture. The level of significance was set at P < 0.05. All data 
presented are expressed as mean ± standard deviation.
Conclusion
In the present study, extrusion was used as a solvent-free 
method to synthesize dense composite materials consisting of 
50 wt% (poly)D,L, lactic acid and 50 wt% nano-sized hydroxy-
apatite, for bone regeneration. While proliferation of hMSCs was 
comparable between the composite and the polymer control not 
containing ceramic, ALP expression was higher on the compos-
ite materials. Furthermore, intramuscular implantation in dogs 
of composite implants produced using an innovative design, 
resulted in heterotopic bone formation, in contrast to polymer- 
based implants, which were not osteoinductive.
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